Ms. Linda Sampson of Marapharm reports

MARAPHARM VENTURES INC. PROVIDES AN UPDATE OF ITS INVESTMENT STRATEGY WITH VERITAS PHARMA INC.

"Marapharm's focus is on corporate growth and excellence by acquisitions, operations and investments. Marapharm invested in Veritas Pharma Inc. (news releases dated Jan. 9 and Jan. 11, 2017, Marapharm purchased 15 million shares and rights to acquire shares), and to date, this investment has increased substantially in value. The synergy with Veritas and Marapharm and the development of both company's products enhances corporate and shareholder value over all. Medical research by Veritas scientists can help to monetize Marapharm's intellectual properties and products of subsidiaries currently under development. Marapharm, with the assistance of Veritas, intends to advance its cannabis strains. With our unique vertical grow system, yields and quality will be maximized. We think Veritas is a great business model and investment in the cannabis space. Marapharm is the majority owner and largest shareholder of Veritas," said Linda Sampson, Marapharm Ventures Inc. chief executive officer.

Veritas and/or its subsidiary Cannevert Therapeutics Ltd. have designed and are implementing clinical trials of cannabis strains for pain. Health Canada has granted permission to conduct research. Chemical and animal studies by Veritas have identified suitable strains that warrant immediate human trials, which are intended to be implemented this year. The management team consists of veteran academic pharmacologists, anesthetists and chemists, whose commercial mission is to patent its findings to sell or license to cancer clinics and pharmaceutical companies, thereby, targeting multibillion-dollar global markets.

We seek Safe Harbor.